Osiris Therapeutics is a regenerative medicine company involved research, development and manufacturing of product in orthopedics, sports medicine and wound care. Key products include the Grafix product line which includes Stravix, BIO4 and Cartiform.
Timeline
April 17, 2019
Smith & Nephew Completes Acquisition of Osiris Therapeutics,
Smith & Nephew plc today announces completion of the acquisition of Osiris Therapeutics, Inc. for $19.00 per share in cash, representing a total equity value of approximately $660 million.
Funding rounds
People
Name
Role
LinkedIn
Further reading
Title
Author
Link
Type
Date
Subscribe to read | Financial Times
Arash Massoudi
Web
Documentaries, videos and podcasts
Title
Date
Link
Companies
Company
CEO
Location
Products/Services
News
Title
Author
Date
Publisher
Description
Brad Perriello
March 27, 2019
MassDevice
The Medical Device Business Journal -- Medical Device News & Articles | MassDevice
Brad Perriello
March 12, 2019
MassDevice
The Medical Device Business Journal -- Medical Device News & Articles | MassDevice
Brad Perriello
December 14, 2018
MassDevice
The Medical Device Business Journal -- Medical Device News & Articles | MassDevice
References
Is a
CompanyCompany attributes
Biotechnology
Healthcare
Tissue engineering
Regenerative medicine
Stem cellLocation
Columbia, MarylandCrunchbase
Parent organization
Smith & NephewCIK number
Place of incorporation
MarylandInvestors
SOSVIRS number
710,881,115
Founded date
December 23, 1992
Latest funding round date
2018
Stock symbol
OSIR
Stock exchange
NASDAQLatest funding type
Seed round
United StatesCategories
Related Topics
Contributors
- 1
Meredith Hanel
Medical Genetics PhD, following life science applications that improve the health of humans and our planet. - 2
Dawson Sewell
Writing about startups. - 3
Keeri Tramm
Accomplished manager, brand communicator, and burgeoning data analyst. - 4
Jude Gomila
Founder and CEO of Golden, Entrepreneur. Investor in 200+ companies. Cantabrigian (Gonville and Caius). Interested in the Universe.